In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
With regard to increasing the clinical potential of ricin A-chain immunotoxins (RTA-ITs), a novel class of calcium channel blockers, indolizines SR33557 [2-isopropyl-1-[4-(3-N-methyl-N-(3,4-dimethoxy-beta- phenethyl)amino)propyloxy)benzenesulfonyl))indolizine] and SR33287 [isopropyl-2-((1-butylamino-3-propyl)oxy-4-benzoyl)-3-indolizine], were evaluated for their ability to enhance RTA-IT activity in vitro and in vivo. Five microM SR33287 and 5 microM SR33557 were potent enhancers of both anti-Thy 1.2 AT15E RTA-IT (84- and 64-fold, respectively) on T2 cells and anti-CD5 T101 (622- and 538-fold) and T101 F(ab')2 RTA-IT (34- and 28-fold) on CEM III cells. This was superior to the effect achieved by both 10 microM verapamil and 10 mM NH4Cl, albeit slightly inferior to that of 50 nM monensin and 5 microM perhexiline. Murine T2 lymphoma cells bearing the Thy 1.2 antigen were injected i.v. in Thy 1.2 (-) BL. 1.1 mice (median survival time, 17.7 days). Intravenous treatment with 10 micrograms of AT15E RTA-IT prolonged the survival of mice (median survival time, 26.8 days). When 400 micrograms of SR33287 were coinjected i.v. with 10 micrograms of AT15E RTA-IT, mouse survival was further increased, with 5 of 6 mice surviving, disease free, over 42 days. SR33287 had a significant impact on the intracellular routing of 125I-AT15E RTA-IT, which induced a greater than 2-fold increase in intracellular intact AT15E RTA-IT at 90 min. This effect on RTA-IT half-life was distinctly different from that observed with either NH4Cl or monensin and may be linked to the inhibition of acid lysosomal sphingomyelinase by SR33287, leading to cellular lipidosis. In conclusion, indolizines appear to be promising agents not only for immunotoxin enhancement but also for increasing the activity of any number of targeted therapeutic agents where modifying either the intracellular routing or increasing the intracellular half-life of the ligand would be beneficial to its cytotoxic activity.
Jaffrézou
J P
JP
Laboratoire de Pharmacologie et de Toxicologie Fondamentales, Centre Hospitalier Universitaire Rangueil, Toulouse, France.
Levade
T
T
Thurneyssen
O
O
Chiron
M
M
Bordier
C
C
Attal
M
M
Chatelain
P
P
Laurent
G
G
D000643:Ammonium Chloride / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006801:Humans; D000922:Immunotoxins / Q000378:metabolism / Q000627:therapeutic use*; D007212:Indolizines / Q000494:pharmacology*; D008064:Lipidoses / Q000139:chemically induced / Q000378:metabolism; D016399:Lymphoma, T-Cell / Q000378:metabolism / Q000628:therapy*; D008985:Monensin / Q000494:pharmacology; D010480:Perhexiline / Q000494:pharmacology; D010627:Phenethylamines / Q000494:pharmacology*; D012276:Ricin / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured; D014700:Verapamil / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D007212:Indolizines; D010627:Phenethylamines; D000643:Ammonium Chloride; C072909:SR 33287; D012276:Ricin; D008985:Monensin; D014700:Verapamil; C059901:fantofarone; D010480:Perhexiline